Geode Capital Management’s GSK GSK Stock Holding History

Geode Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-144,050	Closed	-$7.94M	–	4990
2021 Q4	$7.94M	Sell	144,050 -2,463	-2%	-$128K	﹤0.01%	2607
2021 Q3	$7M	Buy	146,513 +5,754	+4%	+$289K	﹤0.01%	2715
2021 Q2	$7.01M	Buy	140,759 +19,500	+16%	+$937K	﹤0.01%	2701
2021 Q1	$5.41M	Buy	121,259 +6,916	+6%	+$314K	﹤0.01%	2753
2020 Q4	$5.26M	Sell	114,343 -9,038	-7%	-$415K	﹤0.01%	2576
2020 Q3	$5.8M	Sell	123,381 -17,804	-13%	-$892K	﹤0.01%	2305
2020 Q2	$7.2M	Sell	141,185 -7,580	-5%	-$389K	﹤0.01%	2120
2020 Q1	$7.04M	Sell	148,765 -56,437	-28%	-$3.01M	﹤0.01%	1945
2019 Q4	$12.1M	Buy	205,202 +64,041	+45%	+$3.56M	﹤0.01%	1882
2019 Q3	$7.53M	Buy	141,161 +16,546	+13%	+$851K	﹤0.01%	2120
2019 Q2	$6.23M	Sell	124,615 -110,179	-47%	-$5.53M	﹤0.01%	2255
2019 Q1	$12.3M	Sell	234,794 -104,724	-31%	-$5.23M	﹤0.01%	1754
2018 Q4	$16.2M	Buy	339,518 +38,781	+13%	+$1.91M	0.01%	1433
2018 Q3	$15.1M	Buy	300,737 +131,795	+78%	+$6.7M	﹤0.01%	1618
2018 Q2	$8.51M	Buy	168,942 +22,860	+16%	+$1.15M	﹤0.01%	2001
2018 Q1	$7.13M	Buy	146,082 +29,665	+25%	+$1.38M	﹤0.01%	2011
2017 Q4	$5.16M	Sell	116,417 -58,884	-34%	-$2.72M	﹤0.01%	2196
2017 Q3	$8.9M	Buy	175,301 +40,167	+30%	+$2.04M	﹤0.01%	1814
2017 Q2	$7.28M	Buy	135,134 +31,818	+31%	+$1.7M	﹤0.01%	1876
2017 Q1	$5.44M	Buy	103,316 +32,686	+46%	+$1.66M	﹤0.01%	2046
2016 Q4	$3.4M	Sell	70,630 -4,328	-6%	-$214K	﹤0.01%	2311
2016 Q3	$4.04M	Buy	74,958 +95	+0.1%	+$5.21K	﹤0.01%	2099
2016 Q2	$4.05M	Sell	74,863 -12,043	-14%	-$634K	﹤0.01%	2054
2016 Q1	$4.41K	Buy	86,906 +5,252	+6%	+$262K	﹤0.01%	1950
2015 Q4	$4.12M	Buy	81,654 +12,071	+17%	+$615K	﹤0.01%	2000
2015 Q3	$3.34M	Buy	69,583 +1,270	+2%	+$66.1K	﹤0.01%	2110
2015 Q2	$3.56M	Buy	68,313 +12,337	+22%	+$695K	﹤0.01%	2133
2015 Q1	$3.23M	Buy	55,976 +3,538	+7%	+$203K	﹤0.01%	2125
2014 Q4	$2.8M	Sell	52,438 -5,878	-10%	-$329K	﹤0.01%	2215
2014 Q3	$3.35M	Buy	58,316 +618	+1%	+$37.9K	﹤0.01%	2013
2014 Q2	$3.86M	Buy	57,698 +25,610	+80%	+$1.73M	﹤0.01%	1949
2014 Q1	$2.14M	Sell	32,088 -2,525	-7%	-$171K	﹤0.01%	2293
2013 Q4	$2.31M	Buy	34,613 +27,470	+385%	+$1.78M	﹤0.01%	2207
2013 Q3	$448K	Hold	7,143	–	–	﹤0.01%	3000
2013 Q2	$446K	Buy	+7,143	New	+$453K	﹤0.01%	2941

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Geode Capital Management's GSK Position: Q1 2022 in Review

Geode Capital Management sold out of GSK (GSK) in Q1 2022, closing a stake of 144,050 shares — an estimated $7.94M sold.

Geode Capital Management first reported a position in GSK in Q2 2013 and held it in 35 quarters. The position peaked at $16.2M in Q4 2018. 929 funds tracked by Wall St. Rank hold GSK as of Q1 2022.

Geode Capital Management reported no remaining GSK position as of Q1 2022 after selling out during the quarter.
Geode Capital Management sold 144,050 GSK shares in Q1 2022, an estimated $7.94M.
Geode Capital Management first reported a position in GSK in Q2 2013 and held it in 35 quarters.
Geode Capital Management's GSK position peaked at $16.2M in Q4 2018.
929 funds tracked by Wall St. Rank held GSK as of Q1 2022.

Based on Geode Capital Management's 13F filing for Q1 2022, filed 13 May 2022.